PMID- 26659436
OWN - NLM
STAT- MEDLINE
DCOM- 20160919
LR  - 20200615
IS  - 1680-0745 (Electronic)
IS  - 1995-1892 (Print)
IS  - 1015-9657 (Linking)
VI  - 26
IP  - 6
DP  - 2015 Nov-Dec
TI  - Protective effects of ginseng extracts and common anti-aggregant drugs on 
      ischaemia-reperfusion injury.
PG  - 222-6
LID - 10.5830/CVJA-2015-047 [doi]
AB  - OBJECTIVE: Ginseng is a traditional herbal medicinal product widely used for 
      various types of diseases because of its cellular protective effects. Possible 
      protective effects of ginseng were investigated in blood, cardiac and renal 
      tissue samples and compared with common anti-aggregant agents in an animal 
      ischaemia-reperfusion (I/R) model. METHODS: Twenty rats were equally divided into 
      four different groups as follows: control group (I/R-induced group without drug 
      use), group I (acetylsalicylic acid-administered group), group II (clopidogrel 
      bisulfate-administered group), group III (ginsenoside Rb1-administered group). 
      For the groups assigned to a medication, peripheral I/R was induced by clamping 
      the femoral artery one week after initiation of the specified medication. After 
      reperfusion was initiated, cardiac and renal tissues and blood samples were 
      obtained from each rat with subsequent analysis of nitrogen oxide (NOx), 
      malondialdehyde (MDA), paraoxonase 1 (PON1) and prolidase. RESULTS: NOx levels 
      were similar in each group. Significant decrements were observed in serum PON1 
      levels in each group when compared with the control (p < 0.05). Serum MDA levels 
      were significantly lower in groups II and III (p < 0.05). Ameliorated renal 
      prolidase levels were detected in study groups (p < 0.05) and recovered cardiac 
      prolidase levels were obtained in groups II and III (p < 0.05). CONCLUSION: These 
      findings indicate that ginseng extracts may have a potential beneficial effect in 
      I/R injury. However, more comprehensive studies are required to clarify the 
      hypothetical cardiac, renal and systemic protective effects in 
      reperfusion-induced oxidative damage.
FAU - Caliskan, Ahmet
AU  - Caliskan A
AD  - Department of Cardiovascular Surgery, Medical School of Dicle University, 
      Diyarbakir, Turkey. drahmetcaliskan@hotmail.com.
FAU - Karahan, Oguz
AU  - Karahan O
AD  - Department of Cardiovascular Surgery, Medical School of Dicle University, 
      Diyarbakir, Turkey.
FAU - Yazici, Suleyman
AU  - Yazici S
AD  - Department of Cardiovascular Surgery, Medical School of Dicle University, 
      Diyarbakir, Turkey.
FAU - Demirtas, Sinan
AU  - Demirtas S
AD  - Department of Cardiovascular Surgery, Medical School of Dicle University, 
      Diyarbakir, Turkey.
FAU - Guclu, Orkut
AU  - Guclu O
AD  - Department of Cardiovascular Surgery, Medical School of Dicle University, 
      Diyarbakir, Turkey.
FAU - Tezcan, Orhan
AU  - Tezcan O
AD  - Department of Cardiovascular Surgery, Medical School of Dicle University, 
      Diyarbakir, Turkey.
FAU - Yavuz, Celal
AU  - Yavuz C
AD  - Department of Cardiovascular Surgery, Medical School of Dicle University, 
      Diyarbakir, Turkey.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - South Africa
TA  - Cardiovasc J Afr
JT  - Cardiovascular journal of Africa
JID - 101313864
RN  - 0 (Biomarkers)
RN  - 0 (Ginsenosides)
RN  - 0 (Plant Extracts)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Protective Agents)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - 4Y8F71G49Q (Malondialdehyde)
RN  - 7413S0WMH6 (ginsenoside Rb1)
RN  - A74586SNO7 (Clopidogrel)
RN  - EC 3.1.1.2 (Pon1 protein, rat)
RN  - EC 3.1.8.1 (Aryldialkylphosphatase)
RN  - EC 3.4.13.- (Dipeptidases)
RN  - EC 3.4.13.9 (proline dipeptidase)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aryldialkylphosphatase/blood
MH  - Aspirin/*pharmacology
MH  - Biomarkers/blood
MH  - Clopidogrel
MH  - Dipeptidases/blood
MH  - Disease Models, Animal
MH  - Femoral Artery/surgery
MH  - Ginsenosides/isolation & purification/*pharmacology
MH  - Kidney/drug effects/metabolism
MH  - Ligation
MH  - Malondialdehyde/blood
MH  - Myocardium/metabolism
MH  - Nitric Oxide/blood
MH  - Oxidative Stress/drug effects
MH  - Panax/*chemistry
MH  - Phytotherapy
MH  - Plant Extracts/isolation & purification/*pharmacology
MH  - Plants, Medicinal
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Protective Agents/isolation & purification/*pharmacology
MH  - Rats
MH  - Reperfusion Injury/blood/etiology/*prevention & control
MH  - Ticlopidine/*analogs & derivatives/pharmacology
PMC - PMC4780024
EDAT- 2015/12/15 06:00
MHDA- 2016/09/20 06:00
PMCR- 2015/11/01
CRDT- 2015/12/15 06:00
PHST- 2014/03/27 00:00 [received]
PHST- 2015/04/12 00:00 [accepted]
PHST- 2015/12/15 06:00 [entrez]
PHST- 2015/12/15 06:00 [pubmed]
PHST- 2016/09/20 06:00 [medline]
PHST- 2015/11/01 00:00 [pmc-release]
AID - 10.5830/CVJA-2015-047 [doi]
PST - ppublish
SO  - Cardiovasc J Afr. 2015 Nov-Dec;26(6):222-6. doi: 10.5830/CVJA-2015-047.